Filters
Save & Share
Clear Filters
Location
Explore options near your home - or near family and friends.
Trials Near Add Your Location
Accepting patients
TAPUR
Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer (TAPUR)
Learn more- ROS1 Inhibitor
- Phase 2
Accepting patients
CARE Study
A Phase 1/2, Open-Label, Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity Study of Repotrectinib in Pediatric and Young Adult Subjects With Advanced or Metastatic Malignancies Harboring ALK, ROS1, NTRK1-3 Alterations
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trialsAccepting patients
Cabozantinib
A Phase II Study of Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 2
- Has results
Accepting patients
Larotrectinib
A Phase II Basket Study of the Oral TRK Inhibitor Larotrectinib (BAY2757556) in Subjects With NTRK Amplification Positive and Pan-TRK Positive Tumors
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 2
Accepting patients
ON-TRK
PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib
Learn more- Tyrosine Kinase (TK) Inhibitor
- PI3K Inhibitor
- Tyrosine Kinase (TK) Inhibitor
- CDK6
- Phase 2
Accepting patients
VMD-928
An Open-Label, Multiple-Dose, Dose-Escalation Study to Investigate the Safety, Pharmacokinetics, and Pharmacodynamics of VMD-928 in Subjects With Solid Tumors or Lymphoma
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 1
Accepting patients
Larotrectinib
A Pilot and Surgical Study of Larotrectinib for Treatment of Children With Newly-Diagnosed High-Grade Glioma With NTRK Fusion
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 1
Accepting patients
TRIDENT-1
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 1/2
- Has results
Accepting patients
TY-2136b
A Phase I, Multicenter, Open-label Study of TY-2136b, Administered Orally in Patients With Advanced or Metastatic Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations
Learn more- Tyrosine Kinase (TK) Inhibitor
- Phase 1